Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after one systemic treatment


23 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of axicabtagene ciloleucel in the NHS in England.

Axicabtagene ciloleucel is not recommended for the treatment of adults with diffuse large B-cell lymphoma that has relapsed within 12 months after first-line chemoimmunotherapy or is refractory to first-line chemoimmunotherapy.

Read NICE appraisal consultation document

Michael Wonder

Posted by:

Michael Wonder